Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Mackensen

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|April 22, 2016
Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndromeSimon Völkl, Anne Rensing-Ehl, Andrea Allgäuer, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating LymphocytesFranziska Würfel, Ramona Erber, Hanna Huebner, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapyHannah Reimann, Andrew Nguyen, J Zachary Sanborn, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Eclinicalmedicine|February 16, 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeRaffaella Greco, Tobias Alexander, Nicoletta Del Papa, et al.
The New England Journal of Medicine|February 21, 2024
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-upFabian Müller, Jule Taubmann, Laura Bucci, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Frontiers in Immunology|November 15, 2023
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 studyArmin Gerbitz, Regina Gary, Michael Aigner, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|April 22, 2016
Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndromeSimon Völkl, Anne Rensing-Ehl, Andrea Allgäuer, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating LymphocytesFranziska Würfel, Ramona Erber, Hanna Huebner, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapyHannah Reimann, Andrew Nguyen, J Zachary Sanborn, et al.
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Eclinicalmedicine|February 16, 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeRaffaella Greco, Tobias Alexander, Nicoletta Del Papa, et al.
The New England Journal of Medicine|February 21, 2024
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-upFabian Müller, Jule Taubmann, Laura Bucci, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Frontiers in Immunology|November 15, 2023
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 studyArmin Gerbitz, Regina Gary, Michael Aigner, et al.
Pageof 20